XSTO
ISOFOL
Market cap24mUSD
Oct 09, Last price
0.80SEK
1D
3.10%
1Q
-3.86%
IPO
-97.00%
Name
Isofol Medical AB (publ)
Chart & performance
P/E
—
P/S
—
EPS
—
Div yield, %
—
Shrs. gr., 5y
22.75%
Rev. gr., 5y
-11.85%
Revenues
0
Net income
-54m
L+24.56%
CFO
-52m
L+23.70%
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Isofol Medical AB (publ) is a clinical-stage biotechnology firm dedicated to the research, marketing, and global distribution of oncology medications, with operations both in Sweden and abroad. Its leading therapeutic candidate, arfolitixorin, is presently undergoing Phase 3 clinical trials for individuals with advanced colorectal cancer. The company has forged significant strategic alliances with organizations including Recipharm, Merck & Cie, and Sahlgrenska University Hospital. Established in 2008, its corporate base is situated in Gothenburg, Sweden.
Key people
Petter Lindqvist
Chief Executive Officer · since 2024
Magdalena Hagman
Chief Financial Officer · since 2024
Jenny Sundqvist
Chief Commercial Officer · since 2022
Anders Edvell
Director · since 2023
Independent Director · since 2024
Independent Director · since 2021
Lars Lind
Independent Director · since 2024
Independent Director · since 2024
Helena Taflin
Independent Director · since 2024
Headquarters & legal address
C/O Biotech Center, Arvid Wallgrens
Backe 20, 5 tr
Göteborg, O 413 46
SE
Backe 20, 5 tr
Göteborg, O 413 46
SE
Address
C/O Biotech Center, Arvid Wallgrens
Backe 20, 5 tr
Goteborg, O 413 46
SE
Backe 20, 5 tr
Goteborg, O 413 46
SE
Previous name
Isofol Medical AB
Valuation
Title SEK in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2022‑12 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||
Revenues | ||||||||||
Cost of revenue | ||||||||||
Unusual Expense (Income) | ||||||||||
NOPBT | ||||||||||
NOPBT Margin | ||||||||||
Operating Taxes | ||||||||||
Tax Rate | ||||||||||
NOPAT | ||||||||||
Net income | ||||||||||
Dividends | ||||||||||
Dividend yield | ||||||||||
Proceeds from repurchase of equity | ||||||||||
BB yield | ||||||||||
| Debt | ||||||||||
Debt current | ||||||||||
Long-term debt | ||||||||||
Deferred revenue | ||||||||||
Other long-term liabilities | ||||||||||
Net debt | ||||||||||
| Cash flow | ||||||||||
Cash from operating activities | ||||||||||
CAPEX | ||||||||||
Cash from investing activities | ||||||||||
Cash from financing activities | ||||||||||
FCF | ||||||||||
| Balance | ||||||||||
Cash | ||||||||||
Long term investments | ||||||||||
Excess cash | ||||||||||
Stockholders' equity | ||||||||||
Invested Capital | ||||||||||
ROIC | ||||||||||
ROCE | ||||||||||
| EV | ||||||||||
Common stock shares outstanding | ||||||||||
Price | ||||||||||
Market cap | ||||||||||
EV | ||||||||||
EBITDA | ||||||||||
EV/EBITDA | ||||||||||
Interest | ||||||||||
Interest/NOPBT | ||||||||||